Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year
Advertisement

Related Content

Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Avastin Breast Cancer Approval Memo Comes Back To Haunt FDA’s Pazdur
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings
Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings
MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
Second Part Of Essential Drug List Will Cover More Therapeutic Areas, Says China's Minister Of Health
Advertisement
UsernamePublicRestriction

Register

SC078622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel